NAV

Ribose

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ribose
DrugBank Accession Number
DB15073
Background

Ribose is under investigation in clinical trial NCT01727479 (Ribose and Sport Performance).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 150.1299
Monoisotopic: 150.05282343
Chemical Formula
C5H10O5
Synonyms
  • aldehydo-D-ribose
  • D-ribo-2,3,4,5-tetrahydroxyvaleraldehyde
  • D-Ribose
  • Ribose

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
681HV46001
CAS number
50-69-1
InChI Key
PYMYPHUHKUWMLA-LMVFSUKVSA-N
InChI
InChI=1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h1,3-5,7-10H,2H2/t3-,4+,5-/m0/s1
IUPAC Name
(2R,3R,4R)-2,3,4,5-tetrahydroxypentanal
SMILES
[H]C(=O)[C@H](O)[C@H](O)[C@H](O)CO

References

General References
Not Available
ChemSpider
4470639
RxNav
1314858
ChEBI
47014
ZINC
ZINC000018168713
PDBe Ligand
RB5
Wikipedia
Ribose
PDB Entries
3ph3 / 6nch / 6nci

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatment5'-Nucleotidase Syndrome1
2CompletedTreatmentFibromyalgia1
2CompletedTreatmentHeart Failure, Diastolic1
2RecruitingTreatmentClear Cell Renal Cell Carcinoma (ccRCC) / Locally Advanced Malignant Solid Neoplasm / Locally Advanced Pancreatic Cancer (LAPC) / Metastatic Malignant Solid Neoplasm / Metastatic Renal Cell Carcinoma ( mRCC) / Metastatic Ureter Urothelial Carcinoma / Pancreatic Metastatic Cancer / Stage III Pancreatic Cancer / Stage III Renal Cell Cancer / Stage IV Pancreatic Cancer / Stage IV Renal Cell Cancer1
2WithdrawnTreatmentCongestive Heart Failure (CHF)1
1Active Not RecruitingTreatmentBreast Neoplasm Malignant Female / Breast Neoplasms, Triple-Negative / Radiotherapy Side Effects1
1RecruitingTreatmentSolid Tumors, Advanced Solid Tumors1
1, 2Not Yet RecruitingTreatmentCarcinoma, Ovarian / Fallopian Tube Carcinosarcoma / Ovarian Cancer / Platinum-resistant Ovarian Cancer (PROC) / Primary Peritoneal Cancer1
1, 2TerminatedTreatmentSolid Tumors1
0Active Not RecruitingTreatmentProstate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility380.0 mg/mLALOGPS
logP-2.3ALOGPS
logP-2.9ChemAxon
logS0.4ALOGPS
pKa (Strongest Acidic)12.34ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area97.99 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity31.38 m3·mol-1ChemAxon
Polarizability13.39 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 MEOX; 4 TMS)GC-MSsplash10-0udi-1920000000-2a376699e06455c76ff7
GC-MS Spectrum - GC-MS (1 MEOX; 4 TMS)GC-MSsplash10-0uxr-0941000000-7b9d79f55ddb22a39810
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at May 20, 2019 14:47 / Updated at June 12, 2020 16:53